Retatrutide, a novel dual agonist of the GLP-1 binding site and glucose-dependent released polypeptide (GIP) target, is showing promising data in preliminary patient assessments . Current research https://artybookmarks.com/story21181277/retatrutide-emerging-research-and-potential-therapeutic-roles